Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cytocom Inc | NASDAQ:CBLI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.17 | 3.18 | 3.41 | 0 | 00:00:00 |
FORM 8-K
|
Delaware
|
001-32954
|
20-0077155
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
2537 Research Boulevard, Suite 201
Fort Collins, CO 80526
|
||
(Address of Principal Executive Offices and zip code)
|
||
(888) 613-8802
|
||
(Registrant's Telephone Number, Including Area Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.005
|
STAB
|
NASDAQ Capital Market
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Emerging growth company ☐ |
Item 2.04.
|
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.
|
●
|
timely deliver monthly financial statements for certain periods;
|
●
|
obtain Avenue’s consent to repurchase certain securities from stockholders;
|
●
|
pay principal and interest when due, including on March 1, 2022; and
|
●
|
maintain unrestricted cash and cash equivalents in one or more accounts subject to control agreements in favor of Avenue in amount of at least $5 million.
|
Item 3.01.
|
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
17.1
|
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
Statera Biopharma, Inc.
|
|||
Date: March 31, 2022
|
By:
|
/s/ Cozette McAvoy
|
|
Name:
|
Cozette McAvoy
|
||
Title:
|
Chief Legal Officer
|
1 Year Cytocom Chart |
1 Month Cytocom Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions